Novel Metabolic Disease Therapy
First Claim
Patent Images
1. Use of a FAP selective inhibitor for one or more of:
- controlling blood glucose level;
increasing insulin secretion;
decreasing glucagon secretion;
increasing β
cell mass and insulin gene expression;
inhibiting acid secretion and gastric emptying in the stomach;
decreasing food intake by increasing satiety.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the prevention and treatment of metabolic abnormalities characterized by abnormal glucose metabolism, including diabetes mellitus and new onset diabetes mellitus through the use of fibroblast activation protein (FAP) selective inhibitors.
-
Citations
11 Claims
-
1. Use of a FAP selective inhibitor for one or more of:
-
controlling blood glucose level; increasing insulin secretion; decreasing glucagon secretion; increasing β
cell mass and insulin gene expression;inhibiting acid secretion and gastric emptying in the stomach; decreasing food intake by increasing satiety. - View Dependent Claims (5, 6, 7, 8, 9, 10, 11)
-
-
2. A method of preventing or treating one or more of the following diseases or conditions:
-
impaired glucose tolerance; impaired fasting glucose; insulin resistance; new onset diabetes mellitus; metabolic syndrome; diabetes mellitus; hepatic steatosis; the method including providing a FAP selective inhibitor to an individual having one or more the above diseases or conditions, or to an individual susceptible for one or more of the above diseases or conditions. - View Dependent Claims (3, 4)
-
Specification